home / stock / jazz / jazz news


JAZZ News and Press, Jazz Pharmaceuticals plc From 06/19/22

Stock Information

Company Name: Jazz Pharmaceuticals plc
Stock Symbol: JAZZ
Market: NASDAQ
Website: jazzpharmaceuticals.com

Menu

JAZZ JAZZ Quote JAZZ Short JAZZ News JAZZ Articles JAZZ Message Board
Get JAZZ Alerts

News, Short Squeeze, Breakout and More Instantly...

JAZZ - 3 Stocks That Could Double by 2025

Bear markets don't last forever. They also give forward-thinking investors plenty of opportunities to buy great stocks at a discount. We asked three Motley Fool contributors to identify stocks they think could double by 2025. Here's why they chose Axsome Therapeutics (NASDAQ: AXSM...

JAZZ - Avadel: Further Delay, But Some Light At The End Of The Tunnel

AVDL's FT218 is going to get delayed further over a patent issue. However, there's a goalpost in sight now, and the date is June 2023. The company is cash-strapped. For further details see: Avadel: Further Delay, But Some Light At The End Of The Tunnel

JAZZ - 2 Cheap Stocks to Buy Right Now

The stock market still faces various geopolitical and economic issues, including supply chain problems and interest rate hikes in the U.S. and elsewhere that may impact corporations' bottom lines. In this climate, stocks that look overvalued are more likely to suffer since investors tend to...

JAZZ - Jazz to start clinical trial for tumor candidate after FDA nod

Jazz Pharmaceuticals (NASDAQ:JAZZ) is set to initiate a clinical trial for pan-RAF inhibitor JZP815 developed by its partner Redx after the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application, the companies announced on Wednesday. The agency has gree...

JAZZ - Jazz initiated Buy at UBS on underappreciated potential of cannabidiol drug

UBS has launched its coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy rating and a $194 per share target, arguing that investors have underestimated the growth prospects of Ireland-based pharma’s cannabidiol drug, Epidiolex. Jazz (JAZZ) recorded ~6% growth of Epidiolex net pro...

JAZZ - 3 Marijuana Stocks That May See A Turnaround In Trading This Month

Will These 3 Marijuana Stocks See A Recovery Mid-June? Will marijuana stocks start to see better momentum from the success of the cannabis industry? Many publicly traded cannabis companies are making more headway outside of the market than in it. For example companies like Trulieve ...

JAZZ - Best Cannabis Stocks To Buy? 3 To Watch Long Term In June

Top Ancillary Cannabis Stocks For June 2022 Are you looking for the best marijuana stocks to invest in for the long term? The best cannabis stocks to watch right now are recognized for having high market volatility, making it difficult for long-term investors to find stability. Long...

JAZZ - Jazz Pharmaceuticals: Strong Launch Of Xywav In Idiopathic Hypersomnia

Jazz Pharmaceuticals missed first quarter revenue estimates, but management raised the full-year guidance. The launch of Xywav in idiopathic hypersomnia looks strong, and has driven the best quarter for the oxybate franchise since mid-2020. Business development activity picked up ...

JAZZ - Jazz's new dosing regimen of Rylaze as part of cancer chemotherapy shows promise in trial

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported data from a phase 2/3 trial of a new dosing regimen of its therapy Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn). The results — which were presented at the American Society of Clinical Oncology (ASCO) meetin...

JAZZ - Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting PR Newswire Oral presentation confirms pati...

Previous 10 Next 10